Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Ali, Naushad ^a,b,c   Allam, Heba ^a,e   Bader, Ted ^a,c   May, Randal ^a,c   Basalingappa, Kanthesh M ^a   Berry, William L ^a   Chandrakesan, Parthasarathy ^a   Qu, Dongfeng ^a   Weygant, Nathaniel ^a   Bronze, Michael S ^a   Umar, Shahid ^d   Janknecht, Ralf ^a,b   Sureban, Sripathi M ^a,b,c   Huycke, Mark ^a,b,c   Houchen, Courtney W ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; FATTY ACIDS, MONOUNSATURATED; HEPACIVIRUS; HEPATOCYTES; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROTUBULES; PROTEIN-SERINE-THREONINE KINASES; VIRUS REPLICATION;

EID: 84894119487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080304     Document Type: Article

References (46)

1. Qu L, Lemon SM (2010) Hepatitis a and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Semin Liver Dis 30: 319-332.
2. El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273 e1261.
3. Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5: 453-463. (Pubitemid 46780082)
4. Bartenschlager R, Penin F, Lohmann V, Andre P (2011) Assembly of infectious hepatitis C virus particles. Trends in microbiology 19: 95-103.
5. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45: 164-171.
6. Vermehren J, Sarrazin C (2011) New HCV therapies on the horizon. Clin Microbiol Infect 17: 122-134.
7. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44.
8. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, et al. (2012) A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57: 24-31.
9. Bader T, Fazili J, Madhoun M, Aston C, Hughes D, et al. (2008) Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 103: 1383-1389. (Pubitemid 351813920)
10. Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB (2010) Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci 55: 190-195.
11. Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, et al. (2013) Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J Gastroenterol Hepatol 28: 51-56.
12. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, et al. (2010) Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 52: 864-874.
13. Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, et al. (2009) An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 52: 43-48.
14. Bader T HL, Fazili J, et al. (2013) A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype 1 hepatitis C patients. J Viral Hepat In Press.
15. Milazzo L, Meroni L, Galazzi M, Cesari M, Caramma I, et al. (2009) Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat 16: 479-484.
16. Clendening JW, Penn LZ (2012) Targeting tumor cell metabolism with statins. Oncogene 31: 4967-4978.
17. Kapadia SB, Chisari FV (2005) Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102: 2561-2566. (Pubitemid 40279416)
18. Wang C, Gale M, Jr., Keller BC, Huang H, Brown MS, et al. (2005) Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 18: 425-434. (Pubitemid 40704757)
19. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, et al. (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44: 117-125. (Pubitemid 44049145)
20. Ali N, Allam H, May R, Sureban SM, Bronze MS, et al. (2011) Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol 85: 12292-12303.
21. Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, et al. (2013) Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 45: 98-103.
22. Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, et al. (2009) Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 137: 649-659, 659 e641-642.
23. Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, et al. (2011) DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 71: 2328-2338.
24. Lin PT, Gleeson JG, Corbo JC, Flanagan L, Walsh CA (2000) DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization. J Neurosci 20: 9152-9161. (Pubitemid 32042918)
25. Lai CK, Jeng KS, Machida K, Lai MM (2008) Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A. J Virol 82: 8838-8848.
26. Wolk B, Buchele B, Moradpour D, Rice CM (2008) A dynamic view of hepatitis C virus replication complexes. J Virol 82: 10519-10531. (Pubitemid 352691191)
27. Syed GH, Amako Y, Siddiqui A (2010) Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21: 33-40.
28. Syed GH, Siddiqui A (2011) Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus. Hepatology 54: 1936-1946.
29. Wu X, Robotham JM, Lee E, Dalton S, Kneteman NM, et al. (2012) Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 8: e1002617.
30. Nelson HB, Tang H (2006) Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. J Virol 80: 1181-1190. (Pubitemid 43134075)
31. Ali N, Tardif KD, Siddiqui A (2002) Cell-free replication of the hepatitis C virus subgenomic replicon. J Virol 76: 12001-12007. (Pubitemid 35304300)
32. Guo JT, Bichko VV, Seeger C (2001) Effect of alpha interferon on the hepatitis C virus replicon. Journal of virology 75: 8516-8523. (Pubitemid 32768956)
33. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature medicine 11: 791-796. (Pubitemid 41021213)
34. Shimakami T, Yamane D, Jangra RK, Kempf BJ, Spaniel C, et al. (2012) Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A 109: 941-946.
35. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581. (Pubitemid 41266486)
36. Wen J, Friedman JR (2012) miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 122: 2773-2776.
37. Hsu SH, Wang B, Kota J, Yu J, Costinean S, et al. (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122: 2871-2883.
38. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, et al. (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122: 2884-2897.
39. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5: 930-942. (Pubitemid 41766782)
40. Vaughan CJ, Gotto AM, Jr. (2004) Update on statins: 2003. Circulation 110: 886-892. (Pubitemid 39096019)
41. da Costa RF, Freire VN, Bezerra EM, Cavada BS, Caetano EW, et al. (2012) Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations. Phys Chem Chem Phys 14: 1389-1398.
42. Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, et al. (2009) Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 50: 6-16.
43. Yang H, Ganguly A, Cabral F (2010) Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem 285: 32242-32250.
44. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
45. Checchi PM, Nettles JH, Zhou J, Snyder JP, Joshi HC (2003) Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci 24: 361-365. (Pubitemid 37315528)
46. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.